the cutoff probability: typically, \(\theta = [0.95, 0.99]\) for superiority, \(\theta = [0.01, 0.05]\) for futility.
type
type of boundaries: "superiority" or "futility".
nmax
the maximum number of patients treated by the experimental drug.
alpha_e
the hyperparameter (shape1) of the Beta prior for the experimental drug.
beta_e
the hyperparameter (shape2) of the Beta prior for the experimental drug.
alpha_s
the hyperparameter (shape1) of the Beta prior for the standard drug.
beta_s
the hyperparameter (shape2) of the Beta prior for the standard drug.
delta
the minimally acceptable increment of the response rate for the experimental drug compared with the standard drug.
Note: if type = "superiority", then delta is set to 0.
Value
boundset
the boundaries set; \(U_n\) or \(L_n\)
References
Thall, P. F., Simon, R. (1994).
Practical Bayesian guidelines for phase IIB clinical trials.
Biometrics50: 337-349.
Yin, G. (2012).
Clinical Trial Design: Bayesian and Frequentist Adaptive Methods.
New York: Wiley.